Catalent Pharma Solutions has successfully completed its collaboration with BioAlliance Pharma on the development, approval and launch of Miconazole 50mg buccal tablets for the treatment of oropharyngeal candidiasis. The product has been marketed in several European countries since 2007 under the name Loramyc, and was approved by the FDA in April. The product has launched in the U.S. under the trade name Oravig, by Strativa Pharmaceuticals Inc., a division of Par Pharmaceuticals. Catalent provides the manufacturing and packaging for Oravig.
“The launch of Oravig in the U.S. market is a major step for BioAlliance, as it opens up the largest market worldwide. We are pleased to share this success with Catalent, which has ensured industrial development through a close collaboration with our teams,” said Dominique Costantini, chief executive officer of BioAlliance Pharma.
“We are proud that we could once again prove that we are the preferred partner for pharmaceutical companies looking for innovative solutions for solid oral dose formulations for any market in the world,” said Eric Schmidhaeuser, managing director of Catalent’s Schorndorf operation.
Visit Catalent at Contract Pharma's Contracting & Outsourcing Conference!